200 related articles for article (PubMed ID: 20430177)
1. The effect of cytomegalovirus antigenemia titer on the efficacy of preemptive therapy for the prevention of cytomegalovirus disease after kidney transplantation.
Jung GO; Kim SJ; Choi GS; Moon JI; Kim JM; Sin MJ; Kim EY; Kwon CH; Joh JW; Lee SK
Transplant Proc; 2010 Apr; 42(3):804-10. PubMed ID: 20430177
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation.
Kim CK; Song JH; Kim SM; Peck KR; Oh W; Huh W; Kim YG; Kim SJ; Joh JW; Lee NY; Park CG; Hwang ES; Cha CY; Oh HY
Transplantation; 2003 Jun; 75(12):2151-5. PubMed ID: 12829929
[TBL] [Abstract][Full Text] [Related]
4. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
[TBL] [Abstract][Full Text] [Related]
6. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus infection and disease following renal transplantation: preliminary report of incidence and potential risk factors.
Taherimahmoudi M; Ahmadi H; Baradaran N; Montaser-Kouhsari L; Salem S; Mehrsai A; Kalantar E; Jahani Y; Pourmand G
Transplant Proc; 2009 Sep; 41(7):2841-4. PubMed ID: 19765452
[TBL] [Abstract][Full Text] [Related]
8. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M
Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863
[TBL] [Abstract][Full Text] [Related]
9. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
[TBL] [Abstract][Full Text] [Related]
10. The impact of pretransplant cytomegalovirus infection on acute renal allograft rejection.
Chen JH; Mao YY; He Q; Wu JY; Lv R
Transplant Proc; 2005 Dec; 37(10):4203-7. PubMed ID: 16387078
[TBL] [Abstract][Full Text] [Related]
11. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
12. Real-time PCR assay compared with antigenemia assay for detecting cytomegalovirus infection in kidney transplant recipients.
Kim DJ; Kim SJ; Park J; Choi GS; Lee S; Kwon CD; Ki C; Joh J
Transplant Proc; 2007 Jun; 39(5):1458-60. PubMed ID: 17580161
[TBL] [Abstract][Full Text] [Related]
13. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.
Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J
Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066
[TBL] [Abstract][Full Text] [Related]
14. Strategies for prevention of cytomegalovirus infection in renal transplant patients.
Valenzuela M; Ortiz AM; Troncoso P; Vilches S
Transplant Proc; 2009; 41(6):2673-5. PubMed ID: 19715999
[TBL] [Abstract][Full Text] [Related]
15. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
[TBL] [Abstract][Full Text] [Related]
16. [Cytomegalovirus infection after heart transplantation. Retrospective analysis of an antiviral CMV prevention].
Antretter H; Höfer D; Klaus A; Larcher C; Margreiter J; Margreiter R
Dtsch Med Wochenschr; 2000 Apr; 125(15):445-51. PubMed ID: 10800441
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of viral load and antigenemia as markers for relapse cytomegalovirus infection in renal transplant recipients].
Franco A; Serrano R; Gimeno A; de Juan J; Merino E; Jiménez del Cerro L; Olivares J
Nefrologia; 2007; 27(2):202-8. PubMed ID: 17564566
[TBL] [Abstract][Full Text] [Related]
18. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
19. Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation.
Lianghui G; Shusen Z; Tingbo L; Yan S; Weilling W; Anwei L
Transplant Proc; 2004 Jun; 36(5):1502-5. PubMed ID: 15251371
[TBL] [Abstract][Full Text] [Related]
20. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
Ozaki KS; Pestana JO; Granato CF; Pacheco-Silva A; Camargo LF
Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
